Business Context and Reporting Period
Company: McKesson Corporation (MCK)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2002
Business Overview: McKesson is the world's largest healthcare service and technology company, operating through three segments: Pharmaceutical Solutions (93% of revenue), Medical-Surgical Solutions (5%), and Information Solutions (2%). The company distributes pharmaceuticals and medical supplies, provides automated dispensing systems, and delivers healthcare information technology solutions.
Key Financial Metrics
| Metric | Fiscal 2002 | Fiscal 2001 | Fiscal 2000 |
|---|---|---|---|
| Total Revenues | $50,006.0 million | $42,019.1 million | $36,708.0 million |
| Gross Profit | $2,796.9 million (5.6% margin) | $2,429.1 million (5.8% margin) | $2,223.4 million (6.1% margin) |
| Net Income (Loss) | $418.6 million | $(48.3) million | $723.7 million |
| Diluted EPS | $1.43 | $(0.17) | $2.55 |
| Operating Cash Flow | $329.3 million | $332.3 million | $(314.8) million |
| Total Debt | $1,429.6 million | $1,229.7 million | $1,260.0 million |
| Stockholders' Equity | $3,940.1 million | $3,492.9 million | $3,565.8 million |
| Debt to Capital Ratio | 25.7% | 25.0% | 25.1% |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 19% to $50.0 billion, driven primarily by the Pharmaceutical Solutions segment (up 20% excluding sales to customers' warehouses). Growth was attributed to increased volume from retail chains and institutional customers.
- Profitability Recovery: The company returned to profitability with $418.6 million in net income, reversing a $48.3 million loss in 2001. This improvement was aided by the adoption of SFAS No. 142, which eliminated goodwill amortization, and margin expansion in the Pharmaceutical segment.
- Special Charges: Pre-tax special charges decreased significantly to $88.5 million in 2002, compared to $458.3 million in 2001. The 2001 figure was heavily impacted by a $161.1 million charge for customer settlements in the Information Solutions segment and $97.8 million in investment impairments.
- Segment Performance: Information Solutions operating profit improved to $21.7 million from a loss of $295.1 million in 2001, largely due to higher-margin software sales and the absence of large restructuring charges.
Guidance, Outlook, Risks, and Contingencies
Management Commentary: Management emphasizes that pro forma results (excluding special charges and discontinued operations) provide a better view of recurring operations. Pro forma net income increased 55% to $439.2 million. The company expects continued revenue growth driven by pharmaceutical distribution and generic drug offerings.
Significant Risks and Contingencies:
- Accounting Litigation: As of May 10, 2002, 91 lawsuits remain pending related to the 1999 restatement of financial statements regarding improper revenue recognition at the former HBOC unit. The company states it is not feasible to predict the outcome or estimate potential losses, which could be material.
- Customer Concentration: Sales to the ten largest customers accounted for 55% of total revenues in 2002. The largest customer, Rite Aid Corporation, represented 14% of revenues. Default or reduced purchases by these customers could materially impact financial condition.
- Regulatory Environment: Changes in healthcare financing, Medicare reimbursement, and potential FDA regulation of software as medical devices pose risks to the Information Solutions segment.
- Environmental Liabilities: The company has accrued approximately $14.1 million for remediation costs at five former chemical sites and $1.1 million for Superfund sites.
Investor Verification Checklist
- Customer Concentration: Verify the stability of relationships with the top 10 customers, particularly Rite Aid (14% of revenue), given the high concentration risk.
- Litigation Exposure: Monitor the status of the 91 pending securities lawsuits regarding the 1999 accounting restatement and any potential settlement amounts.
- Information Solutions Turnaround: Assess the sustainability of the operating profit recovery in the Information Solutions segment, which previously suffered massive restructuring and settlement charges.
- Goodwill Accounting: Note that 2002 results exclude goodwill amortization due to SFAS No. 142; compare pro forma metrics to GAAP metrics to understand the impact of this accounting change.
- Working Capital: Review the increase in operating working capital ($3.7 billion) to ensure it aligns with sales growth and does not indicate collection issues.